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Objectives. The purpose of this study was to prospectively 
examine in a multicenter study the methods of use, efficacy and 
complications of a unipolar cardioverter-defibrillator in patients 
at risk for sudden cardiac death. 
Background. Implantation ofcardioverter-defibrillators in the 
pectoral region offers a significant opportunity to improve the 
management of patients with life-threatening arrhythmias. 
Unipolar, single-lead, pectoral implantable cardioverter- 
defibrillators might decrease related mortality, morbidity and 
costs in the care of such patients. 
Methods. From November 3, 1993 to May 8, 1995, a unipolar 
defibrillator (Medtronic model 7219C) was selected for use in 473 
patients from 74 centers (386 [82%] men, 87 [18%] women; mean 
[-+SD] age 59 - 13 years, range 16 to 88). The clinical indication 
for use was ventricnlar fibrillation in 157 patients, sustained 
ventricular tachycardia n 236, both ventricular tachycardia and 
ventricular fibrillation in 53 and syncope or inducible ventricular 
tachycardia/ventricular fibrillation in 27. Coronary artery disease 
was present in 323 patients (68%). The mean left ventricular 
ejection fraction was 0.36 + 0.15 (range 0.10 to 0.85). The 
distribution of New York Heart Association congestive heart 
failure was class I = 34%; class II = 45%; class I I I=  17%; and 
class IV = 2%. 
Results. The unipolar cardioverter-defibrillator was inserted 
successfully in 464 (98%) of 473 candidates. Effective defibrilla- 
tion occurred with the first shock polarity tested in 88% of 
patients, after a polarity switch in 8% and after lead or generator 
repositioning in 2%. The stored energy defibrillation threshold 
was obtained at implantation i  339 patients (72%) and was 
11.5 + 6.1 J, with 72% of patients having a defibrillation threshold 
<12 J. The mean "skin-to-skin" implantation time was 96 + 
45 min (range 25 to 335 min). Complications occurred in 29 
patients (6%). Device therapy for 2,160 spontaneous ventricular 
tachycardia orfibrillation episodes occurred in 128 patients (27%) 
over a 2,732 device-month experience (range 0 to 17.2) and was 
effective in98.7% of episodes. There were 14 deaths (10 nonsudden 
cardiac, 3 sudden cardiac, 1 noncardiae). Cumulative survival, on 
an intention-to-treat basis from all causes of death at 17.2 
months, was 94.4%. 
Conclusions. Unipolar pectoral implantable cardioverter- 
defibrillators can be inserted with a high likelihood of success in 
a relatively brief procedure. Defibrillation thresholds are low, 
morbidity is modest, and survival rates are good with this new 
type of implantable cardioverter-defibriUator. 
(J Am Coil Cardio11996;28:400-10) 
Unipolar single-lead pectoral implantable cardioverter- 
defibrillators offer an opportunity to decrease treatment- 
related mortality, morbidity and costs in the care of patients 
with life-threatening ventricular arrhythmias. Unipolar defi- 
brillation systems use only one transvenous defibrillation elec- 
trode and the housing of the cardioverter-defibrillator itself as 
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the second active defibrillation electrode; bipolar defibrillation 
systems use two separate transvenous electrodes, typically one 
in the right ventricle and one in the superior vena cava. A 
unipolar cardioverter-defibrillator is inserted in a manner 
similar to a unipolar pacemaker and, as a result of its relative 
simplicity, may reduce the morbidity and cost of this therapy. 
These changes are similar to the positive ffects that followed 
the transition from epicardial to transvenous lead systems for 
antibradycardia devices (1,2). 
Early reports of the use of unipolar pectoral defibrillation 
systems, henceforth called unipolar cardioverter-defibrillators 
for simplicity, have shown that defibrillation thresholds are 
comparable tothose of epicardial lead systems and better than 
those of more complicated nonthoracotomy lead systems (3- 
5). Defibrillation efficacy notwithstanding, the overall clinical 
efficacy of unipolar cardioverter-defibrillators ha  yet to be 
described. It is the purpose of this report to describe the 
methods of use, overall clinical efficacy and complications of a 
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unipolar cardioverter-defibrillator in a multicenter, interna- 
tional study of patients at risk of sudden cardiac death. 
Methods  
Patients. From November 3, 1993 to May 8, 1995, a 
unipolar cardioverter-defibrillator was selected for use in 
patients from 22 European and 52 North American centers for 
the treatment ofventricular fibrillation or ventricular tachycar- 
dia. A cohort of 473 patients (131 European, 342 North Ameri- 
can) were enrolled for unipolar cardioverter-defibrillator the apy 
after provision of informed verbal and written consent. 
Patients were eligible for this study if they had either 
survived a cardiac arrest unrelated to an acute transmural 
myocardial infarction or had recurrent ventricular tachycardia 
unresponsive to antiarrhythmic drug therapy. Patients were 
excluded from the study if they had ventricular tachyarrhyth- 
mias associated with reversible causes, had mechanical right 
heart valves, had hemodynamically well-tolerated ventricular 
tachycardia, were inaccessible for follow-up, were judged by 
the investigator to be unable to accommodate infraclavicular 
placement of the unipolar cardioverter-defibrillator or were 
unable to provide informed consent. Consecutive nrollment 
of all eligible patients was not required by the protocol. 
A special enrollment circumstance arose in June 1994 in 
most implantation centers in the United States after a federal 
mandate by the Health Care Financing Administration pro- 
scribed the use of investigational cardiac therapies inMedicaid 
or Medicare patients from June 1994 onward. Consequently, 
poor and elderly U.S. patients requiring implantable 
cardioverter-defibrillator herapy were largely excluded from 
the latter half of this study. 
Unipolar defibrillation system. The unipolar defibrillation 
lead (Medtronic model 6936; lead length 58, 65 or 75 cm) was 
10.5F, tripolar, polyurethane and placed endocardially in the 
right ventricle. The 5-cm endocardial coil electrode at the 
distal end of the lead was used for cardioversion and defibril- 
lation. Two more distal electrodes were used for bipolar pacing 
and sensing. The defibrillator housing (108 cm 2 surface area, 
80-ml pulse generator, Medtronic model 7219C) was com- 
posed of an electrically active titanium shell electrode used in 
combination with the 5-cm endocardial right ventricular coil 
electrode for unipolar defibrillation. 
Implantation technique. All patients underwent cardioverter- 
defibrillator testing during implantation. The protocol did not 
specify whether the implant could be performed in an operat- 
ing room, a cardiac catheterization laboratory or an electro- 
physiology laboratory; whether a surgeon or a cardiologist 
would perform the implant; what type of anesthesia would be 
administered; whether the device was placed subcutaneously 
or subpectorally; what approach to venous access would be 
taken; how postoperative monitoring would be done; or how 
long the patient would remain in the hospital. 
Defibrillation testing. At implantation, ventricular fibrilla- 
tion was induced through the implantable cardioverter- 
defibrillator or an external cardioverter-defibrillator (Med- 
tronic model 5358) using a low energy shock on the T wave, 
50-Hz stimulation, burst stimulation or programmed lectrical 
stimulation according to the physician's preference, or, in some 
cases, alternating current from an external source was used to 
induce ventricular fibrillation. The successful method of induc- 
tion was recorded for each episode. 
The initial shock energy chosen to terminate ventricular 
fibrillation was 24 J, with a biphasic 65% tilt and 120-/zF 
capacitor pulse (6). The recommended polarity for the initial 
defibrillation test was with the right ventricular defibrillation 
electrode as negative for the initial phase of the biphasic shock. 
An active titanium-shell electrode was used to emulate the 
unipolar cardioverter-defibrillator f r testing defibrillation ef- 
ficacy before implantation of the fully functional unipolar 
cardioverter-defibrillator. The defibrillation criterion was suc- 
cess with a _<24-J biphasic shock in two of two consecutive 
attempts or in three of four consecutive attempts. Neverthe- 
less, the ultimate decision to implant he system was up to the 
investigator. This procedural f exibility allowed physicians to 
contend with the occasional patient who was not inducible into 
ventricular fibrillation or who deteriorated during the proce- 
dure before all testing could be completed. 
As part of the study protocol, every effort was made to 
determine the biphasic defibrillation threshold, except when 
the managing physician judged its measurement to conflict 
with patient safety. Shock strength decreased in6-J steps from 
a starting value of 24 J, with 3-J steps used below 6 J. The 
defibrillation threshold was defined as the lowest shock 
strength to terminate ventricular fibrillation with at least one 
lower energy shock failure. Reconfirmation f the defibrilla- 
tion threshold was not routinely performed. In all patients, all 
tests for defibrillation were recorded so that the lowest energy 
for defibrillation could be determined whenever possible. 
Selection of detection and therapy variables. The recom- 
mended criterion, or "detection i terval," for ventricular fibril- 
lation was 320 ms based on previous experience (7-9). The 
actual detection interval, as well as the activation of slow or 
fast ventricular tachycardia detection zones for antitachycardia 
pacing or low energy cardioversion, and the stability or onset 
criteria for the rejection of atrial fibrillation and sinus tachy- 
cardia, were left to the physician's discretion (9). The nominal 
sensitivity setting was 0.3 mV. 
The energy level for the first therapy of ventricular fibrilla- 
tion, the use of multiple forms of antitachycardia pacing (burst, 
ramp or augmented ramp pacing) and low energy or high 
energy cardioversion pulses for the therapy of monomorphic 
ventricular tachycardia were at the discretion of the managing 
physician, using previously reported techniques (10-14). An- 
tibradycardia VVI pacing was available at rates of 30 to 90 
beats/rain and could be complemented by a hysteresis trigger at 
rates of 30 to 50 beats/min. 
Patient follow-up and event data. After implantation, re- 
testing of pacing, sensing and therapy of ventricular fibrillation 
(and ventricular tachycardia, if applicable) were recommended 
during a predischarge electrophysiologic study. However, post- 
operative lectrophysiologic studies were not mandatory. 
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Patient follow-up included routine postoperative manage- 
ment and outpatient implantable cardioverter-defibrillator in- 
terrogation and evaluation at 1 and 3 to 4 months after 
implantation, and every 3 to 4 months thereafter. Ventricular 
fibrillation, ventricular tachycardia nd bradycardia events 
were stored in the implantable cardioverter-defibrillator mem- 
ory log. Detailed interval data were available for up to five 
tachyarrhythmia events, including 2.5- to 10-s recordings of the 
ventricular tachycardia/ventricular fib illation electrogram. 
Complications were defined as events uch as pneumotho- 
rax, hemothorax, cardiac perforation, hematomas, pocket in- 
fections, lead dislodgments and lead fractures that required 
additional or corrective surgery or invasive procedures. 
Defibrillator-related problems managed with device repro- 
gramming, or simply observed without invasive revision of the 
implantable cardioverter-defibrillator system, were classified as 
observations. 
Deaths were classified as sudden cardiac, nonsudden cardiac 
and noncardiac using previously defined criteria by two clinical 
event review committees, one North American and one Euro- 
pean (15). Operative mortality was defined as death within 30 
days of implantation regardless of the cause. Procedural 
mortality was defined as death on the day of surgery. 
Statistical analysis. Kaplan-Meier survival curves were 
constructed for the end points of all-cause mortality, sudden 
death, occurrence of ventricular tachycardia or ventricular 
fibrillation and complications. Changes in shock impedance 
over time were analyzed using a repeated measures model, 
including covariates indicating submuscular or subcutaneous 
placement of the implantable cardioverter-defibrillator. To 
account for the dependence of measurements within an indi- 
vidual, analysis of defibrillation efficacy thresholds and imped- 
ance over time was done using the repeated measures ap- 
proach in PROC MIXED in SAS (16). 
Serial defibrillation thresholds were measured in a sub- 
group of patients during implantation, predischarge testing 
and at the 3-month follow-up electrophysiologic study. The 
measurement of the defibrillation threshold is highly depen- 
dent on the starting point when using the step-down approach 
(17,18). The repeated measures model used to test for differ- 
ences at various follow-up times and between subcutaneous 
and submuscular implant locations incorporated not only 
adjustments for age, gender, ejection fraction and body mass 
index, but also adjustments for the starting point for the 
step-down procedure, defibrillation impedance and missing 
observations at some time points; p values <0.05 were consid- 
ered statistically significant. 
Results 
Implantation data. Of the 473 patients eligible for therapy 
with a unipolar defibrillator, 464 (98%) received the device. 
The clinical characteristics of these patients are detailed in 
Table 1. The mean "skin-to-skin" implantation time was 96 +_ 
45 min (range 25 to 335). The mean hospital stay from the time 
of implantation to the predischarge valuation was 2.6 +_ 2.2 
Table 1. Clinical Characteristics of 473 Study Patients 
All Study Patients Not 
Patients Receiving a Unipolar 
(n = 473) ICD (n = 9 of 473) 
Male 386 (82%) 8 (89%) 
Female 87 (18%) 1 (11%) 
Mean age (yr) 59 _+ 13 53 -+ 16 
Range 16-88 21-76 
Weight (kg) 81 + 17 84 + 32 
Range 36-169 63-166 
Primary indication 
Clinical history of VF only 157 (33%) 3 (33%) 
Clinical history of VT only 236 (50%) 6 (67%) 
Clinical history of VF and VT 53 (11%) -- 
Other (syncope/inducible VT/VF) 27 (6%) -- 
Primary CV 
CAD/ischemic CM 239 (50%) 5 (56%) 
Nonischemic CM 78 (16%) 4 (44%) 
CAD/ischemic and nonischemic CM 82 (17%) 
Other 74 (17%) -- 
Mean EF 0.36 _+ 0.15 0.21 + 0.06* 
Range 0.10-0.85 0.13-0.30 
NYHA functional classt 
I 159 (34%) 3 (33%) 
II 213 (45%) 3 (33%) 
III 81 (17%) 3 (33%) 
IV 9 (2%) 0 (0%) 
*Only measure that differed from 464 patients who received a unipolar 
implantable cardioverter-defibrillator (p = 0.0035). tNot measured in all pa- 
tients because all patients did not have heart failure. Data presented are mean 
value +_ SD, range or number (%) of patients. CAD = coronary artery disease; 
CM = cardiomyopathy; CV = cardiovascular; EF = ejection fraction; NYHA 
New York Heart Association; Other = idiopathic ventricular fibrillation, right 
ventricular dysplasia, long QT syndrome, congenital heart disease and valvular 
heart disease; VF = ventricular fibrillation; VT = ventricular tachycardia. 
days (range 1 to 17) for U.S. centers, 4.2 + 2.6 days (range 1 to 
14) for Canadian centers and 6.7 +_ 2.6 days (range 2 to 19) for 
European centers, (p = 0.0001). The analysis of variance 
model used to test for differences between geographies incor- 
porated adjustments for age, gender, ejection fraction and 
body mass index. 
The unipolar cardioverter-defibrillator was placed in a left 
infraclavicular subcutaneous pocket in 228 patients (48%) or in 
a left subpectoral muscle pocket in 239 patients (51%). Right- 
sided unipolar cardioverter-defibrillator implantations were 
performed in 5 patients (1%). For the five patients receiving 
right-sided implants, two had a preexisting pacemaker in the 
left pectoral region (the lowest energy for defibrillation being 
24 J in both), two had an infected nonthoracotomy i plantable 
cardioverter-defibrillator removed earlier from the left side 
(defibrillation threshold 24 J, lowest energy for defibrillation 
6 J) and one had a previous left pectoral implantable 
cardioverter-defibrillator (defibrillation threshold 12 J). 
The right ventricular endocardial electrode was inserted 
into the left subclavian vein in 299 patients (63%), the left 
cephalic vein in 156 (33%), the left internal jugular vein in 5 
(1%), the right subclavian vein in 10 (2%) and the right 
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Figure l. Chest radiograph from a cardiac arrest survivor with a 
unipolar implantable cardioverter-defibrillator. 
cephalic vein in 1 (0.2%). Once inserted, the lead was posi- 
tioned in the right ventricular apex in 447 patients (95%) or in 
a right ventricular septal location in 24 (5%). The typical pulse 
generator and lead position are shown in Figure 1. 
At the time of cardioverter-defibrillator implantation, ven- 
tricular fibrillation was induced through the implantable 
cardioverter-defibrillator r the external cardioverter- 
defibrillator (Medtronic model 5358) using a low energy shock 
on the T wave (84%) or using 50-Hz stimulation (13%) using 
the right ventricular lead. Alternating current from an external 
source was applied to induce ventricular fibrillation in 3% of 
patients. Burst stimulation and programmed electrical stimu- 
lation were used in 0.2% and 0.4% of patients, respectively. Six 
patients (1%) were noninducible. 
The mean unipolar stored energy defibrillation threshold in 
339 patients (72%) was 11.5 + 6.1 J for the initial polarity 
tested. The defibrillation threshold was -<12 J in 72% of those 
having a defibrillation threshold measured. Implantation was 
done with the first system polarity tested in 88% of patients. A
switch in shock polarity raised the total to 96%. In an 
additional 2%, successful implantation of the unipolar system 
was achieved after repositioning of the right ventricular lead or 
the generator. Ultimately, 98% of patients received the unipo- 
lar system. 
Of the 464 patients receiving a unipolar cardioverter- 
defibrillator, the recommended implantation criterion-- 
successful termination of ventricular fibrillation twice with 
consecutive -<24-J shocks--was not satisfied in 32 (6.8%) of 
473 patients. Of these 32 patients, ventricular arrhythmias were 
noninducible in 6, another 6 did not complete testing because 
they were unstable clinically and 20 did not meet the defibril- 
lation implant criteria during testing. Nevertheless, these 32 
patients underwent unipolar cardioverter-defibrillator place- 
ment (see survival data). 
Nine of the original 473 patients did not receive a unipolar 
cardioverter-defibrillator because they did not satisfy the deft- 
brillation implant criterion. Seven of these nine patients re- 
ceived an alternative implantable cardioverter-defibrillator 
(Medtronic model 7219D) that used two or three transvenous 
or subcutaneous electrodes. One patient failed all transvenous 
lead systems tested and later received an epicardial patch 
system. Another patient failed testing with multiple trans- 
venous lead systems and did not receive any device. The 
clinical characteristics of these nine patients are described in 
Table 1. They did not differ significantly from the patients who 
received the unipolar cardioverter-defibrillator with respect to 
age, gender, type of structural heart disease, index arrhythmia 
or heart failure class, but they did have a lower mean left 
ventricular ejection fraction--0.21 + 0.06 (p = 0.0035). 
Complications. A total of 31 complications occurred in 29 
patients (6%). Complications included lead dislodgment re- 
quiring lead revision in nine patients (10 events; one patient 
required lead repositioning on two occasions), subcutaneous 
pocket hematoma requiring drainage in five patients and 
inappropriate ventricular fibrillation detection because of a 
loose set screw in two patients. Two patients had pocket pain 
and limitation of arm motion necessitating generator reposi- 
tioning, one patient had increased efibrillation requirements 
requiring lead repositioning, one patient had inappropriate 
ventricular fibrillation therapy because of oversensing, ulti- 
mately requiring lead replacement, and one patient had inap- 
propriate ventricular fibrillation therapy requiring lead re- 
placement because of detection of ambient electromagnetic 
interference. One patient had a lead fracture requiring lead 
replacement (subclavian crush occurring 93 days after implan- 
tation), one patient had a pneumothorax requiring chest ube 
placement and one patient had a hemothorax that was surgi- 
cally drained 12 days after implantation. One patient had a 
right femoral artery occlusion from an embolus (attributable to
an angiogram the day before implantation of the cardioverter- 
defibrillator) and required an emergency embolectomy the day 
after the implantable cardioverter-defibrillator pr cedure. One 
patient developed heart block and subsequent pacemaker 
syndrome that required dual-chamber pacemaker insertion 3 
months after implantation. One patient had a twiddler syn- 
drome requiring lead reanchoring (this patient also had a lead 
dislodgment), one patient had inappropriate l ad anchoring 
requiring revision, one patient had device migration requiring 
reanchoring and one patient had near-incessant ventricular 
tachycardia fter implantation, leading to a catheter ablation 
procedure. No patient experienced pericardial tamponade, 
pocket erosion or pocket infection. There were no complica- 
tions in the nine patients who did not receive the unipolar 
active can system (although one of these patients eventually 
died [see later discussion]). The cumulative complication free 
survival is shown in Figure 2. 
Follow-up and arrhythmia detection and therapy. Prehos- 
pital discharge lectrophysiologic studies were performed in 
382 of the patients who received the unipolar implantable 
cardioverter-defibrillator (382 [81%] of the 473 patients). 
Three-month follow-up electrophysiologic studies were per- 
formed in 248 (52%) of the 473 patients. 
404 BARDY ET AL. JACC Vol. 28, No. 2 
UNIPOLAR PECTORAL DEFIBRILLATION August 1996:400-10 
=_> 
,oo  
90 
80 
70 
60 
91.3% 
0 3 6 9 12 15 18 
n=473 n=303 n=212 n=116 n=37 n=9 
Follow-up (months) 
F igure  2. Compl icat ion- f ree  survival. 
Defibrillation thresholds measured over time are shown in 
Table 2. Overall differences in mean defibrillation thresholds 
between follow-up visits were significant (p = 0.0017), with a 
decrease from implant o prediseharge. The overall difference 
between implantable cardioverter-defibrillator locations was 
not significant (p = 0.55). After adjusting for the effects of 
other factors described in the statistical methods ection, the 
adjusted overall mean defibrillation thresholds were 11.4 J at 
implantation, 8.6 J at predischarge and 9.9 J at 3-month 
follow-up. 
Shock impedances measured over time in nearly all patients 
are also shown in Table 2. Overall differences in mean shock 
impedance between follow-up visits were significant (p < 
0.0001), with a temporary dip of 6 ohms at predischarge. The 
overall difference in mean shock impedance between implant- 
able cardioverter-defibrillator locations was significant (p < 
0.0001); mean shock impedances were 58.9 _+ 7.8 ohms for 
subcutaneous and 52.0 ___ 7.5 ohms for submuscular. 
The average follow-up period for patients receiving the 
unipolar cardioverter-defibrillator was5.8 _+ 4.2 months (range 
0 to 17.2), for a total 2,732 device-months. During this follow- 
up, 128 patients (27%) were treated appropriately for 2,160 
episodes of true ventricular tachycardia, fast ventricular tachy- 
cardia or ventricular fibrillation as classified by the investiga- 
tors. Ventricular tachycardia had been treated in 83 patients 
(1,770 episodes), fast ventricular tachycardia n 12 patients (98 
episodes) and ventricular fibrillation in 69 patients (292 epi- 
sodes). Implantable cardioverter-defibrillator therapy was ef- 
fective in 98.7% of all tachyarrhythmia episodes (98.7% of 
ventricular tachycardia episodes, 98.0% of fast ventricular 
tachycardia episodes and 99.0% of ventricular fibrillation 
episodes). Only one episode of ventricular fibrillation was not 
successfully terminated by all four device therapies, but this 
patient survived repeated back-to-back episodes of a sponta- 
neous, nonsustained polymorphic ventricular tachycardia that 
overwhelmed the detection and therapy capabilities of the 
device. Transthoracic rescue shocks were not delivered, and 
the ventricular tachycardia storm eventually subsided with 
antiarrhythmic drug therapy. Cumulative arrhythmia-free sur- 
vival for the entire 473 patient group is shown in Figure 3. 
The first ventricular tachycardia therapy programmed be- 
fore hospital discharge was antitachycardia pacing in 190 
patients and synchronized cardioversion i 18 patients. Ven- 
tricular tachycardia therapy was not programmed in the re- 
maining 242 patients. 
Sixty-eight patients were inappropriately treated by their 
unipolar cardioverter-defibrillator for atrial fibrillation (n = 
22), sinus tachycardia (n = 30), other supraventricular tachy- 
Table 2. Serial Def ibr i l lat ion Thresho ld  and  Shock Impedance  Data  
Implantation Predischarge* 3 Months? p Value~+ 
Defibrillation Threshold (J) 
Overall n - 339 n = 75 n = 82 
Mean _+ SD 11.5 + 6.1 9.1 + 6.2 8.5 + 5.1 0.0017 
Subcutaneous n 174 n = 35 n = 44 
Mean ± SD 11.6 _+ 6.3 9.2 + 6.6 7.9 ___ 4.2 0.0001 
Submuscular n 165 n = 40 n = 38 
Mean _+ SD 11.3 _+ 5.9 9.1 + 5.9 9.3 +_ 5.9 [).042 
p value§ 0.17 0.33 0.091 
Shock Impedance (ohms) 
Overall n = 426 n = 379 n = 246 
Mean _ SD 57.6 + 7.8 51.5 _* 8.0 57.7 + 7.7 <0.0001 
Subcutaneous n = 208 n = 179 n = 118 
Mean _+ SD 60.9 + 7.3 55.1 _+ 7.3 61.3 + 7.0 <0.0001 
Submuscular n - 218 n = 200 n = 128 
Mean + SD 54.4 + 6.8 48.1 + 6.8 54.3 ___ 6.9 <0.0001 
p value§ <0.0001 <0.0001 <0.0001 
*Data derived from the prehospital discharge lectrophysiologic study. ?Data derived from 3-month follow-up 
electrophysiologic study, :~Statistical comparisons over all three follow-up visits. §Statistical comparisons between 
subcutaneous and submuscular implantable cardioverter-defibrillator locations. 
JACC Vol. 28, No. 2 BARDY ET AL. 405 
August 1996:400-10 UNIPOLAR PECTORAL DEFIBRILLATION 
lOC 
8o 
60 
~ 40 
o 20 
0 
n=473 
l~24.2% 
3 6 9 12 15 
n=268 n=160 n=76 n=23 n=4 
Follow-up (months) 
Figure 3. Cumulative arrhythmia-free survival. 
18 
.Q 
o 
tO 
100 
95 
90 
85 
80 
n=473 
' 99.0% 
94,4"/0 
Total ] 
Sudden 
3 6 9 12 15 18 
n=321 n=228 n=123 n=41 n=9 
Follow-up (months) 
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cardias (n = 3), bigeminy (n = 1), nonsustained ventricular 
tachycardia (n = 6), Y wave oversensing (n = 4), lead 
dislodgment (n = 1) or a loose set screw (n = 1). One of the 
nine patients who did not receive the unipolar implantable 
cardioverter-defibrillator hadinappropriate ventricular tachy- 
cardia therapy owing to sinus tachycardia with the standard 
device that that patient received. 
Antiarrhythmic drugs. The investigational protocol nei- 
ther required nor proscribed antiarrhythmic drug use. Before 
cardioverter-defibrillator implantation, 273 patients (58%) had 
received antiarrhythmic drugs. In those who had received 
antiarrhythmic drugs before cardioverter-defibrillator implan- 
tation, the average number of drugs that had been used was 
1.8 _ 1.1 (range 1 to 7). Amiodarone had been administered in 
139 patients (29%) within the 6 weeks preceding implantable 
cardioverter-defibrillator therapy. 
Antiarrhythmic drugs were used at some time point after 
study enrollment in 246 (52%) of the 473 patients. In this 
subgroup, the average number of antiarrhythmic drugs admin- 
istered, including amiodarone, was 1.3 _+ 0.5 (range 1 to 3). 
The majority of patients receiving antiarrhythmic drugs (159 
[34%]) had the therapy instituted immediately after the pro- 
cedure and before hospital discharge. 
Survival. Cumulative total survival and cumulative sudden 
death-free survival are shown in Figure 4. The total cumulative 
patient survival at 17.2 months was 94.4%. There were a total 
of 14 deaths. There were no deaths on the day of surgery, 
although four deaths (0.85%) occurred within the 30-day 
postoperative period and were classified as perioperative 
deaths. Perioperative deaths occurred 7 days after implanta- 
tion from congestive heart failure in one patient, 16 days after 
implantation from intractable ventricular fibrillation in two 
different patients and 23 days after implantation from conges- 
tive heart failure in the fourth patient. 
Of the 14 deaths, 10 were nonsudden cardiac deaths. Nine 
patients had a nonsudden cardiac death due to congestive 
heart failure, and one died during a new myocardial infarction. 
These deaths occurred 7, 23, 43, 52, 75, 145, 156, 230, 283 and 
308 days after implantation. Three patients had sudden cardiac 
death that was witnessed in the hospital and confirmed elec- 
trocardiographically to be due to refractory ventricular fibril- 
lation. As stated earlier, two of these patients experienced 
sudden cardiac death 16 days after implantation, whereas the 
other patient experienced sudden death 212 days after implan- 
tation. One of the two patients who died 16 days after 
implantation from intractable ventricular fibrillation was the 
one patient who received an epicardial implantable cardioverter- 
defibrillator, as described later. The one noncardiac death 
resulted from sepsis 40 days after implantable cardioverter- 
defibrillator therapy after the patient was readmitted to the 
hospital for pneumonia 14 days after the implantation. 
Survival in the 32 patients who did not meet defibrillation 
criteria, but who nevertheless received the unipolar cardioverter- 
defibrillator, are described herein. (See also implantation data 
regarding these patients.) Two of these 32 patients died. Both 
deaths were attributable torefractory heart failure: one 23 days 
after implantation and one 156 days after implantation, as 
described in the preceding paragraph. Spontaneous ventricular 
fibrillation was effectively treated in 10 of these patients, 
including one of the two patients who eventually died from 
heart failure. In addition, 26 patients had induced ventricular 
fibrillation during postimplant testing, which was successfully 
treated; this includes the 10 patients who also experienced 
spontaneous ventricular fibrillation. Another six patients have 
not yet experienced a spontaneous or induced arrhythmia 
during the study follow-up period. 
All nine patients who did not receive a unipolar 
cardioverter-defibrillator were also included in the survival 
statistics according to the intention-to-treat principle. One of 
these patients died from a sudden cardiac cause during the 
follow-up period. His death was described previously. This 
patient, a 369-1b man, ultimately received an epicardial im- 
plantable cardioverter-defibrillator, but, as with the unipolar 
cardioverter-defibrillator system, defibrillation was not effec- 
tive at the time of implantation. This patient's death was 
witnessed and electrocardiographically documented tobe due 
to ventricular fibrillation refractory to all epicardial and trans- 
thoracic attempts at defibrillation 16 days after implantation. 
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Discuss ion 
The findings from this multicenter, international study show 
that a unipolar cardioverter-defibrillator canbe inserted suc- 
cessfully in 98% of candidates through a single pectoral 
incision. The procedure time for implanting a unipolar 
cardioverter-defibrillator is elatively brief--96 _+ 45 rain-- 
and complications are relatively modest--6%. Defibrillation 
thresholds are low--ll.5 _+ 6.0 J--and successful spontaneous 
ventrieular fibrillation therapy is high--99%. Most important, 
operative mortality is very low with this new type of implant- 
able cardioverter-defibrillator, and cumulative all-cause sur- 
vival on an intention-to-treat basis over the initial 17.2-month 
experience is high--94.4%. These findings suggest hat this 
unipolar cardioverter-defibrillator system provides a safe and 
effective treatment for patients at risk of death from recurrent 
ventricular tachycardia and vcntricular fibrillation, while offer- 
ing advantages of simplicity and ease of use. 
Operative time and hospital period. Three single-center 
studies have commented on the operation time for nonthora- 
cotomy cardioverter-defibrillator implantation in an abdomi- 
nal pocket, and each center has reported mean implant imes 
of 120, 123 and 128 rain, respectively (19-21). The average 
surgical time in our study was 96 _+ 45 rain. These pectoral 
implantable cardioverter-defibrillator procedure times are not 
only less than the nonthoracotomy procedure times, but they 
are comparable to those reported for standard single-lead 
pacemaker implantation (22). 
As is usually the case with standard pacemaker therapy, 
brief implantable cardioverter-defibrillator procedure times, 
coupled with a small, single-incision implant, are likely to favor 
earlier patient recovery and allow overnight hospital stays or 
even outpatient procedures. Indeed, a strong trend already 
exists to shorten hospital stays for such patients (21). If the 
time from implantation to prehospital discharge testing in the 
present study is an indication of hospital use (2.6 _+ 2.2 days in 
U.S. centers), this form of therapy should decrease the dura- 
tion of the hospital period without apparent risk to the patient. 
The differences in the duration of hospital stay between the 
American and European patients in this study--2.6 _+ 2.2 
versus 6.7 _+ 2.6 days (p < 0.0001)--reflecting different prac- 
tice habits, was not associated with a difference in survival or 
complications between the two groups. Indirectly, this finding 
supports the view that hospital periods can be shortened 
without adverse sequelae. 
Defibrillation thresholds. Defibrillation thresholds have 
been shown to be low with unipolar active can systems (3-5). 
The results of this larger multicenter study reinforce earlier 
findings and indicate that implantable cardioverter- 
defibrillators with 34-J outputs hould be sufficient for the vast 
majority of candidates. Less than 2% of patients will fail 
unipolar cardioverter-defibrillator implantation, but the rea- 
sons for failure are unclear. Univariate analysis in this study 
showed that those who failed to defibrillate with a unipolar 
system had a lower ejection fraction. However, a low ejection 
fiaction did not predict defibrillation failure or correlate with 
the defibrillation threshold in multivariate analysis. In an 
earlier controlled study by Raitt et al. (4), no clinical measure, 
including ejection fraction, echocardiographic assessment of
cardiac size and chest radiographic evaluation of heart and 
thoracic dimensions, appeared to predict who would fail left 
pectoral unipolar defibrillation. 
The efficacy of unipolar cardioverter-defibrillators should 
remain high as the cardioverter-defibrillator sizedecreases, at 
least for moderate size reductions. Earlier work in humans has 
shown defibrillation thresholds to remain unchanged even with 
can sizes as small as 40 ml (5). Eventually, though, the 
defbrillation efficacy of unipolar systems i  likely to decrease 
as implantable cardioverter-defibrillator sizebecomes as small 
as today's pacemakers, assuming all other factors responsible 
for defibrillation remain constant. 
Serial defibrillation thresholds with the unipolar implant- 
able cardioverter-defibrillator system used in this study were 
relatively stable. This is in contrast o earlier epicardial and 
nonthoracotomy lead systems in which defibrillation thresholds 
were noted to rise with both monophasic and biphasic pulses 
(23,24). In fact, in our study, defibrillation thresholds generally 
showed a downward trend over time from implant values 
(Table 2). Implantable cardioverter-defibrillator location did 
not, as a rule, affect he defibrillation threshold, although there 
was a slight decrease in shock impedance when a submuscular 
pocket was used. Mean defibrillation thresholds at implanta- 
tion were 11.3 J for submuscular implants and 11.6 J for 
subcutaneous implants, despite associated mean impedance 
values of 54.6 ohm and 60.8 ohm, respectively. This finding 
indicates that submuscular insertion ordinarily should not be 
done if the sole intent is to improve defibrillation. 
Spontaneous ventricular fibrillation/ventricular tachy- 
cardia therapy success rates. Implantable cardioverter- 
defibrillator failure to terminate spontaneous ventricular 
tachycardia/ventricular fibrillation can occur during ischemia, 
end-stage heart disease or drug proarrhythmia. It can also 
result from a programming error or a problem with implant- 
able cardioverter-defibrillator function. Nevertheless, most re- 
cent implantable cardioverter-defibrillator studies report defi- 
brillation and ventricular tachycardia efficacy rates to be >95% 
(25-29). The unipolar implantable cardioverter-defibrillator 
system used in this 473-patient study fits well within this 
experience, with success rates of 98% and 99% for the 
treatment of spontaneous ventricular tachycardia and ventric- 
ular fibrillation, respectively. The only recorded efibrillation 
failure in this study occurred in an individual with salvos of 
rapid, nonsustained polymorphic ventricular tachycardia de- 
tected as "ventricular fibrillation." Although the ventricular 
fibrillation therapy in this individual was unsuccessful, the 
patient survived when the salvos subsided with drug therapy. 
Complications. Use of implantable cardioverter-defibrillator 
therapy has a well-known range of risks that must be weighed 
against he potential benefit of automatic ventricular tachycar- 
dia and ventricular fibrillation therapy (30-34). Reports of 
serious complications with early epicardial lead systems range 
from 9.8% to 32% (25-27,35-39). Such complications have 
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included coronary artery erosions, intrathoracic infections, 
cerebrovascular accidents, pericardial tamponade and phrenic 
nerve injuries (25-27,35-38). Although the incidence of each 
of these complications i  small for epicardial lead systems, the 
consequences of any one of these can be devastating. No such 
complication was observed in the present study. 
Nonthoracotomy lead system implantable cardioverter- 
defibrillators also are associated with significant complication 
rates. However, the types of complications tend to be less 
devastating than those with epicardial systems. In a recent 
nonthoracotomy experience, the incidence of serious compli- 
cations ranged from 5% to 18% (26,27,34,40-43). The com- 
plication rate observed in our study was 6.1%, accounting for 
an actuarial complication-free survival rate of 91.7% at 17.2 
months of follow-up. Although a complication rate of 6.1% is 
less than ideal, it compares favorably with the nonthoracotomy 
experience and reflects the progressive benefits observed with 
advances in technology. 
Some of the complications experienced in our study, such as 
pneumothorax, were inherent o the surgical procedure. Oth- 
ers, though, will likely diminish with further technological 
improvements. For example, advances in lead technology are 
likely to eliminate such annoying problems as loose set screws 
and will minimize lead fractures as lead size decreases and lead 
durability improves. Developments in sutureless anchoring 
systems might minimize the occurrence of lead dislodgment 
that results from inadequately immobilized leads. In the case 
of the implantable cardioverter-defibrillator itself, one can 
expect pocket-related problems uch as hematomas, generator 
migration and interference with shoulder motion to become 
less frequent as the generator size decreases. Thus, it is 
reasonable to anticipate an even lower complication rate with 
future implantable cardioverter-defibrillators than that re- 
ported in this study. 
An unexpected outcome of this study was the complete 
absence of deep pocket infections. Implantable cardioverter- 
defibrillator infection rates have been reported to range from 
1.3% to 5.0% (34,37,44). It is unclear why no deep pocket 
infections were observed in our study, especially given the 
common practice of implanting these devices in locations other 
than an operating room. One could postulate that the pectoral 
dermis is cleaner than that in the abdominal region. Alterna- 
tively, the improvement may result from use of fewer incisions 
and briefer operative procedures. 
Another unanticipated outcome of this study was the 
absence of pocket erosions. A modest incidence of pocket 
erosions could have been anticipated given the 80-ml size of 
the pulse generator. The absence of this complication suggests 
that very small patients, those that could have posed more of a 
problem for pectoral implantation, were excluded from partic- 
ipation in the trial. In contrast, itmay reflect he relatively high 
use of subpectoralis implants. Regardless of the reason for the 
lack of erosions, this concern, and the need for submuscular 
implants, should diminish as implantable cardioverter- 
defibrillator size decreases. 
Survival. In several uncontrolled studies, implantable 
cardioverter-defibrillator therapy has appeared promising for 
the secondary prevention of sudden cardiac death. Survival 
rates have been reported to be 82% to 94% at 2 years, even 
with older nonthoracotomy lead system implantable cardioverter- 
defibrillator technology (8,27,45). Old technology notwith- 
standing, such survival rates are very favorable in an other- 
wise high risk population. Consequently, easy-to-employ 
pacemaker-like implantable cardioverter-defibrillators a e 
likely to have similar or better esults, given the low surgical 
and perioperative mortality that this type of therapy affords 
compared with older technology. 
Effect on implantable cardioverter-defibrUlator therapy 
costs. In an era of increasing cost consciousness regarding 
implantable cardioverter-defibrillator use (46-49), pectoral 
transvenous defibrillators have favorable implications (50). 
The prevention of sudden cardiac death is a major national 
public health goal. New, easier-to-use implantable cardioverter- 
defibrillators could have a broad role in this effort, but any new 
implantable cardioverter-defibrillator therapy to prevent sudden 
cardiac death not only must produce vidence of efficacy but also 
must show that its extra or incremental health benefits are 
produced in proportion to its incremental costs (i.e., these devices 
must be cost effective) in order to be acceptable for large-scale 
implementation (51,52). Although a cost-effectiveness study was 
not performed in this trial, any therapy that decreases operative 
time, duration of hospital stay and complications i very likely to 
improve cost effectiveness, assuming all other factors are equal. 
Study limitations. 1) The favorable outcome, with modest 
complication rates, may reflect he experience ofthe physicians 
and surgeons doing the implanting. The general use of this 
type of implantable cardioverter-defibrillator may lead to a 
surge in implantations by cardiologists, who may have less 
surgical skill. Moreover, implantations are likely to be more 
commonly performed in the cardiac atheterization r electro- 
physiology laboratory rather than in the operating room if 
cardiologists become the primary operators. Complication 
rates could therefore rise from that observed in this study. 
2) No effort was made to evaluate preselection of patients 
for participation. Physician selection of "appropriate" patients 
may have excluded some potential participants, especially 
smaller patients. In addition, because most implanting centers 
in the United States were encumbered from employing inves- 
tigational therapies in Medicaid or Medicare patients from 
June 1994, U.S. patients were likely to be younger and more 
economically advantaged. Poor and elderly U.S. patients re- 
quiring implantable cardioverter-defibrillator herapy were 
therefore largely excluded from this study during its latter half. 
Consequently, the findings of this study may have been differ- 
ent had there been no limitations on inclusion of such patients. 
3) This study is limited by its relatively brief follow-up 
period. Although outcome is favorable arly in the follow-up 
period, morbidity and mortality rates could change in subse- 
quent years. 
4) The lack of a comparison group poses yet another study 
limitation. No effort was made to prove that the simpler 
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implantable cardioverter-defibrillator used in this study 
was superior to multilead or multi-incision implantable 
cardioverter-defibrillator systems. 
5) Reporting of complications was the responsibility of each 
investigator. Independent site monitors were not used in this 
study. Independent review of the medical records of each 
patient might have revealed a higher complication rate. 
Conclusions. The unipolar implantable cardioverter- 
defibrillator used in this study results in operative procedures 
of brief duration, a high likelihood of successful pectoral 
implantation, a relatively low defibrillation threshold, minimal 
procedural morbidity and excellent survival prospects. This 
new form of implantable cardioverter-defibrillator the apy has 
the potential to significantly alter implantable cardioverter- 
defibrillator use and may help minimize the costs and compli- 
cations of this type of therapy. 
Appendix 
Participating Institutions and Investigators for the 
Active Can Trial* 
Hospital Gregorio Marafion (1), Madrid, Spain: J. M. Almendral, Principal 
Investigator, J. Albertos, A. Arenal, J. Villacastin; Freie Universitat Steglitz (2), 
Berlin, Germany: D. Andersen, Principal Investigator, T. Karavias, A. Wondrz- 
inski; HCA-Wesley Medical Center (4), Wichita, KS: Ashok K+ Bajaj, Principal 
Investigator, S. J. Brown, Robert T. Tung; University of Washington Medical 
Center (16), Seattle, WA: Gust H. Bardy, Principal Investigator, G. Lee Dolack, 
Peter J. Kudenchuk, Jeanne E. Poole, Fran Munckenbeck, Marye J. Gleva, Greg 
K. Jones, Ramakota Reddy. Charles Troutman, Jill Anderson, George Johnson; 
Hospital of Good Samaritan (18), Los Angeles, CA: Anil K. Bhandari, Principal 
Investigator, David Cannom, Young M. Park; Westfiilische Wilhdms-Universit~it 
Miinster (4), Miinster, Germany: M. Block, Principal Investigator, G. Breithardt, 
D. Hammel, H. Scheld, N. R6tker, A. Geiger; Ludolf Krehl Klinik, Universi- 
tiitsklinik (29), Heidelberg, Germany: J. Brachmann, Principal Investigator, W. 
Kiibler, W, Sch61s, T. Beyer, M. Schweizer, S.Hagl, R. Lange, H. Mehmanesh; 
Christ Hospital (5), Oak Lawn, IL: Thomas E. Bump, Principal Investigator, 
Bassam Habbal, Principal Investigator, A. Tom Petropulos, Edwin V. Palileo, 
Pierre Abi-Mansour, Liz Ruhwedel; Johns Hopkins Hospital (3), Baltimore, 
MD: Hugh Calkins, Principal Investigator, Ronald Berger, John Lawrence, 
Gordon Tomaselli, Allen Schaeffer, Thomas Guarnieri, Levi Watkins, Lisa Toth; 
Hamilton General (6), Hamilton, Ontario, Canada: Stewart Connolly, Principal 
Investigator, Janice Brent; Robert Packer Hospital (3), Sayre, PA: Pramod 
Deshmukh, Principal Investigator; St. Michael's (7), Toronto, Ontario, Canada: 
Paul Dorian, Principal Investigator, D. Newman, Judy Hardy; The Toronto 
Hospital-University of Toronto (7), Toronto, Ontario, Canada: Eugene Downar, 
Principal Investigator, Eva Radvanszky; Orlando Regional Medical Center (1), 
Orlando, FL: Aurclio Duran, Principal Investigator, Kerry Schwartz, Scott Pollak, 
Luis Alvarez, Maggie Wuofford; Mission Hospital Regional Medical Center (7), 
Mission Viejo, CA: Stephen S. Ehrlich, Principal Investigator, Michael Brodsky, 
Anna Cross; Polidinico Bari Hospital (1), Bari, Italy: S. Favale, Principal 
Investigator, P.Rizzon, M. Pitzalis, C. Forleo, C. Di Candia, G. Luzzi; University 
of California, San Francisco (7), San Francisco, CA: Adam Fitzpatrick, Principal 
Investigator, Leslie Saxon, Principal investigator, Laurence Epstein, Randall J. 
Lee, Jerry C. Griffin, Michael Lesh, Andreana Siu; Fairfax Hospital (2), Falls 
Church, VA: Ted Friehling, Principal Investigator, Albert Del Negro, Marc Wish, 
Kimberly Hill; CHUV Hospital (2), Lausanne, Switzerland: Martin Fromer, 
Principal Investigator, Lukas Kappenberger, A. Fischer, Jurg Schlapfer; Hospitale 
Santa Cbiara (7), Trento, Italy: F. Furlanello, Principal Investigator, G. Vergara; 
Morton Plant Hospital (1), Clearwater, FL: Jose Gallastegui, Principal Investi- 
gator, H. Andrew Hazlitt, Karen Donatello; Victoria Hospital (2), Halifax, Nova 
*Numbers in parentheses indicate the number of patients enrolled at each 
institution. 
Scotia, Canada: Martin Gardner, Principal Investigator, Marcia Shields; Health 
Sciences Centre (1), Winnipeg, Manitoba, Canada: John Geddes, Principal 
lnvesttgator, Kevin B. Wolfe, Darlene Foster; Deborah Heart & Lung (8), Browns 
Mills, NJ: Larry Gessman, Principal m'estigator, William A. Anderson, Javier 
Fernandes, Otto B. Brdlik, Luis D. Berrizbeitia, Melvin C. White, Sivaraman Y.
Raman, Nader Ghaly, Joanne McFie; Laval Hospital (3), Quebec, Ste-Foy, 
Canada: Marcel Gilbert, Principal Investigator, Francois Philippon, Gilles 
O'Hara, Johane Rompre; St. Elizabeth's Hospital (15), Brighton, MA: Charles 
Haffajee, Principal Investigator, Stephanie K. Stevens, Patti Pacetti; Sentara 
Norfolk General Hospital (2), Norfolk, VA: John Herre, Principal Investigator, 
Robert Bernstein, William DeLacey, John Onufer, Bertrand Ross, Linette 
Klaven; Scripps Memorial (2), La Jolla, CA: Steven Higgins, Principal Investi- 
gator, Sardal Singh, Sherie Greer; Klinikum Grosshadern (9), Munich, Ger- 
many: E. Hoffmann, Principal Investigator, G. Steinbeck, S. Mattke, A. 
Markewitz, U. Dorwarth, D. Mttller, J. Schm6ckel, H. Kaulbach; Kaiser-Wilhelm 
Krankenhaus (2), Duisburg, Germany: R. HOltgen, Principal Investigator, R. 
Lyttwin, W. Wanke, W. Kurz; Temple University Hospital (3), Philadelphia, PA: 
Henry Hsia, Primary Investigator, Alfred Buxton, John Miller, Nancy Adelizzi; 
Baptist Memorial Hospital (11), Memphis, TN: David Iansmith, Principal 
Investigator, Paul Hess, Eric Johnson, Barbara Hamilton; Sinai Samaritan 
Medical Center (19), Milwaukee, WI: Mohammad Jazayeri, Principal Investiga- 
tor, Masood Akhtar, Michael Biehl, Sanjay Deshpande, Anwer Dhala, Huagui Li, 
Jasbir Sra, Zalem Blanek, Boaz Avitall, Abdul Wase, Kathi Axtell; Mercy 
Hospital Medical Center (3), Des Moines, IA: W. Ben Johnson, Principal 
Investigator, Steven J. Bailin, Thomas Edel, Robert H. Hoyt, Evelyn Buenting; 
Academisch Ziekcnhuis (9), Gent, Belgium: L. Jordaens, Principal Investigator, F. 
Provenier; Rheiniscbe Friedrich-Wilhelms-Universitat (14), Bonn, Germany: W. 
Jung, Principal Investigator, B.Luderitz, R. Moosdorf, B. Esmailzadeh, M. Manz, 
T. Korte, C. Wolpert, C. Schneider; University of Alberta (5), Edmonton, 
Alberta, Canada: Shane Kimber, Principal Investigator, K. M. Kavanagh, K. 
Paradon; University of Chicago (1), Chicago, IL: Douglas Kopp, Primary 
Investigator, David Wilber, John Kall, Charles Kinder, Marian Stasi; Emory 
University Hospital (2), Atlanta, GA: Jonathan Langberg and Angel Leon, 
Primary Investigators, Paul Walter, A. Gregory Deam, Terrence May, Lisa 
Freschi, Margaret Wade; Eberhard Karls Universitiit (9), Tiibingen, Germany: 
V. Ki.ihlkamp, Principal Investigator, V. Drrnberger, W. Schneider, B. Kobor, J, 
Schulze, D. Bell, O. Mensah; Hospital Sacre Coeur (3), Montreal, Quebec, 
Canada: Teresa Kus, Principal Investigator, Pierre Page, Paolo Costi, Franck 
Molin, Ginette Laudette; Alta Bates Medical Center (6), Berkeley, CA: Randy 
Lieberman, Principal Investigator, Eileen Healy; Broward General Hospital (10), 
Fort Lauderdale, FL: John Lister, Principal Investigator, Charles L. Byrd, Anita 
McCoy; Lankenau Hospital (4), Lankenau, PA: Roger Marinchak, Primary 
Investigator, Peter R. Kowey, Seth J. Rials, Maribel Hernandez, Sheilah Farrell; 
Lahey Clinic Medical Center (13), Burlington, MA: David T. Martin, Principal 
Investigator, Ferdinand J. Venditti, Jr., Roy M. John, Susan Bowen; Abbott 
Northwestern Hospital (2), Minneapolis, MN: Simon Milstein, Principal Inves- 
tigator, Adrian Almquist, Marc Pritzker, Robert Hauser, Linda Kallinen; Foot- 
hills Hospital (11), Calgary, Alberta, Canada: L. Brent Mitchell, Principal 
Investigator, Anne M. Gillis, Robert S. Sheldon, Henry J. Duff, D. George Wyse, 
Darlene Ramadan; Haukeland Hospital (2), Bergen, Norway: O. J. Ohm, 
Principal Investigator, P. I. Hoff, H. Engedal; Methodist Hospital/St. Luke's 
Episcopal Hospital (6), Houston, TX: Antonio Pacifico, Principallnvestigator, All 
Massumkhani, Timothy K. Doyle, Nadim Nasir, Jr., Urlaya S. Swarna, Susan 
Johnson; Sinai Hospital (3), Detroit, MI: Luis Pires, Primary Investigator, Russell 
Steinman, Claudio Schuger, Michael Lehmann, John Boga, Debra Frankovich; 
Rigshospitalet (2), Kopenhagen, Denmark: A. Pietersen, Principal Investigator; 
Washington Hospital Center (15), Washington, DC: Edward Platia, Principal 
Investigator, Susan O'Donoghue, Sandra Waclawski; Wilbelminenspital (7), 
Vienna, Austria: A. Podczeck, Principal Investigator, K. Steinbach, C. Hief, F. 
Veit; Methodist Hospital (1), Memphis, TN: James Porterfield, Primary Investi- 
gator, Linda Porterfield; Albany Medical Center (2), Albany, NY: Arthur 
Portnow, Principal Investigator, Sue Abaffy; Veterans Administration (1), Port- 
land, OR: Merritt Raitt, Principal Investigator, Blair Halperin, Jack Kron, Jack 
McAnulty, Mike Silka, Wendy Nicholson; Providence General Medical Center 
(3), Everett, WA: Jeffrey Rose, Primary Investigator, Grace Buono, Teresa 
Altman; Karolinska Hospital (1), Stockholm, Sweden: M. Rosenqvist, Principal 
Investigator, L. Bergfeldt, M. Runsi6; Passaic General Hospital (2), Passaic, NJ: 
Sanjeev Saksena, Principal Investigator, Kyszard B. Krol, Carolyn Lewis; Allge- 
meines Krankcnbaus (14), Vienna, Austria: H. Schmidinger, Pnncipal Investiga- 
tor, A. Anvari, G. Stix; Klinikum Rechts tier Isar (3), Munich, Germany: C. 
Schmitt, Principal Investigator, H. Kreuzberg, E. Alt, G. Schmitt, A. Plewan; 
Kliniknm der Stadt Ludwigshafen (6), Ludwigshafen, Germany: K. Seidl, 
Principal Investigator, B. Hauer, N. Schwik, W. Saggau, F. Isgro, G. Wollert, H. 
Precht, C. Werling, G. Haisch; Mercy General Hospital (5), Sacramento, CA: 
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Arjun Sharma, Principal Investigator, Gearoid O'Neill, Larry J. Wolff, Stephen I. 
Stark, Anne Skadsen; AIIgemeines Krankenhaus St. Georg (4), Hamburg, 
Germany: J. Siebels, Principal Investigator, K.-H. Kuck, E. Schlemminger; Jewish 
Hospital (5), Louisville, KY: Igor Singer, Primary Investigator, Vaughn Payne, W. 
Jeffrey Schoen, Gregory Deam, Cheryl Williamson; Glenfield Hospital (1), 
Leicester, United Kingdom: J. D. Skehan, Principal Investigator, C. Garratt; Mayo 
Clinic/St. Mary's Hospital (13), Rochester, MN: Marshall Stanton, Principal 
Investigator, Steven C. Hammill, Michael J. Osborn, Win-K Shen, Thomas M. 
Munger, Douglas L. Packer, Jane Trusty, SueEllen Grice; Medtronie Coordi- 
nating Center Personnel: Timothy Church, Cynthia DeSouza, Valerie Stoker; St. 
Luke's Hospital (9), Kansas City, MO: David Steinhaus, Principal Investigator, 
Robert Lemery, Jeffrey Piehler, Loren Berenbom, Debbie Cardinal; St. Francis 
Hospital (1), Tulsa, OK: John Swartz, Primary Investigator, James Cooper, Sheila 
Dewald; Montreal Heart (8), Montreal, Quebec, Canada: Mario Talijic, Principal 
Investigator, Marc Dubuc, Denis Roy, Linda Lavoie; Ottawa Civic (11), Ottawa, 
Ontario, Canada: Anthony Tang, Principal Investigator, M. Green, P. Hendry, W. 
Goldstein, Marilynn Luce; Klinikum der Justus-Liebig-Universit~it (2),Giessen, 
Germany: B. Waldecker, Principal Investigator, H. Killat, H. Hurst, F. Dapper, 
W. A. Stertmann, K. Valeske, M. Wolf, G. G6rlach; Chrisfiana Hospital (1), 
Wilmington, DE: Henry Weiner, Principal Investigator, Raymond Vitullo, Angela 
DiSabatino; Baylor University Medical Center (16), Dallas, TX: Kevin Wheelan, 
Principal Investigator, Peter Wells, Jay Franklin, Marcia K. Seaton; Good 
Samaritan Hospital (6), Cincinnati, OH: John Wilson, Principal Investigator, 
Kim Granneman; University Hospital (10), London, Ontario, Canada: Raymond 
Yee, Principal Investigator, G. J. Klein, Caro Norris, Sally Zandri; Indiana 
University School of Medicine (11), Indianapolis, IN: Douglas Zipes, Principal 
Investigator, William Miles, Lawrence Klein, David Rardon, Raul Mitrani, 
Elizabeth Darling, Lynne Foreman. 
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